Outlook Therapeutics Inc. [NASDAQ: OTLK] traded at a low on 07/30/20, posting a -4.17 loss after which it closed the day’ session at $1.38. The company report on July 17, 2020 that Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the successful closing of its previously announced private placement of 823,045 shares of common stock at a purchase price of $1.215 per share, for aggregate gross proceeds of approximately $1.0 million, to Syntone Ventures LLC, a U.S.-based affiliate of Syntone Technologies Group Co. Ltd. The securities were priced at-the-market under Nasdaq rules.
Outlook Therapeutics intends to use the net proceeds from the financing for working capital and general corporate purposes, including in support of its ONS-5010 development program.
The results of the trading session contributed to over 1562661 shares changing hands. Over the past one week, the price volatility of Outlook Therapeutics Inc. stands at 8.18% while the volatility over the past one month is 9.13%.
The market cap for OTLK stock reached $174.49 million, with 47.90 million shares outstanding and 40.55 million shares in the current float. Compared to the average trading volume of 2.93M shares, OTLK reached a trading volume of 1562661 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Outlook Therapeutics Inc. [OTLK]?
Ladenburg Thalmann have made an estimate for Outlook Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 11, 2019. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on May 16, 2019, representing the official price target for Outlook Therapeutics Inc. stock.
The Average True Range (ATR) for Outlook Therapeutics Inc. is set at 0.13, with the Price to Sales ratio for OTLK stock in the period of the last 12 months amounting to 27.26.
How has OTLK stock performed recently?
Outlook Therapeutics Inc. [OTLK] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -9.80. With this latest performance, OTLK shares gained by 6.98% in over the last four-week period, additionally plugging by 52.07% over the last 6 months – not to mention a drop of -40.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OTLK stock in for the last two-week period is set at 47.50, with the RSI for the last a single of trading hit 44.51, and the three-weeks RSI is set at 52.85 for Outlook Therapeutics Inc. [OTLK]. The present Moving Average for the last 50 days of trading for this stock 1.2605, while it was recorded at 1.4120 for the last single week of trading, and 0.9922 for the last 200 days.
Outlook Therapeutics Inc. [OTLK]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Outlook Therapeutics Inc. [OTLK] shares currently have an operating margin of -301.29. Outlook Therapeutics Inc.’s Net Margin is presently recorded at -424.56.
Additionally, OTLK Total Debt to Total Capital is recorded at 357.90, with Total Debt to Total Assets ending up at 87.23.
Reflecting on the efficiency of the workforce at the company, Outlook Therapeutics Inc. [OTLK] managed to generate an average of -$2,470,368 per employee.Outlook Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.40 and a Current Ratio set at 0.40.
Earnings analysis for Outlook Therapeutics Inc. [OTLK]
With the latest financial reports released by the company, Outlook Therapeutics Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.36/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OTLK.
Insider trade positions for Outlook Therapeutics Inc. [OTLK]
There are presently around $8 million, or 4.90% of OTLK stock, in the hands of institutional investors. The top three institutional holders of OTLK stocks are: SABBY MANAGEMENT, LLC with ownership of 3,232,342, which is approximately 731.073% of the company’s market cap and around 2.00% of the total institutional ownership; ARMISTICE CAPITAL, LLC, holding 1,412,382 shares of the stock with an approximate value of $1.95 million in OTLK stocks shares; and VANGUARD GROUP INC, currently with $0.73 million in OTLK stock with ownership of nearly 67.064% of the company’s market capitalization.
Positions in Outlook Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 19 institutional holders increased their position in Outlook Therapeutics Inc. [NASDAQ:OTLK] by around 4,735,577 shares. Additionally, 6 investors decreased positions by around 126,088 shares, while 6 investors held positions by with 1,209,700 shares. The mentioned changes placed institutional holdings at 6,071,365 shares, according to the latest SEC report filing. OTLK stock had 14 new institutional investments in for a total of 1,643,349 shares, while 6 institutional investors sold positions of 126,088 shares during the same period.